Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $13.8 million.

  • Cumberland Pharmaceuticals' Accounts Payables rose 1471.91% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 1471.91%. This contributed to the annual value of $13.9 million for FY2024, which is 87.88% down from last year.
  • Cumberland Pharmaceuticals' Accounts Payables amounted to $13.8 million in Q3 2025, which was up 1471.91% from $13.4 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Accounts Payables high stood at $14.0 million for Q4 2023, and its period low was $9.0 million during Q2 2021.
  • Its 5-year average for Accounts Payables is $11.7 million, with a median of $11.4 million in 2022.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Accounts Payables crashed by 2803.24% in 2021, and later soared by 2974.97% in 2023.
  • Cumberland Pharmaceuticals' Accounts Payables (Quarter) stood at $9.6 million in 2021, then increased by 12.22% to $10.8 million in 2022, then increased by 29.75% to $14.0 million in 2023, then decreased by 0.88% to $13.9 million in 2024, then decreased by 0.59% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $13.4 million for Q2 2025, and $13.9 million during Q1 2025.